# Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

> **NCT04952467** · PHASE1 · COMPLETED · sponsor: **Xenon Pharmaceuticals Inc.** · enrollment: 6 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** 14C-XEN1101

## Key facts

- **NCT ID:** NCT04952467
- **Lead sponsor:** Xenon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-14
- **Primary completion:** 2021-10-04
- **Final completion:** 2021-10-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952467, "Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04952467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*